News

Archive

New Science Ventures announces merger of its portfolio company Achronix with ACE Convergence NorthSea Therapeutics reports Positive Phase 2b interim results for icosabutate in NASH patients Resolve Therapeutics announces clinically meaningful improvement in patients with Systemic lupus erythematosus in Phase 2a clinical trial Resolve Therapeutics publishes positive Sjogren’s syndrome clinical trial results NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline ProterixBio Announces Commercial Availability of a Semi-Quantitative COVID-19 Antibody Test
Back To News
BrightVolt expands R&D capabilities with new equipment
April 5, 2018

BrightVolt expands R&D capabilities with new equipment

arbin-logo

In Q1 of 2018 BrightVolt added technical personnel and made a substantial investment in new equipment to enhance our solid state battery development. This will help us improve the energy density and performance of our new solid state rechargeable batteries. BrightVolt’s first rechargeable batteries are expected to debut in Q3 of this year.

Our new solid state rechargeable battery product line will benefit from a new Keyence Digital Microscope, a new Metrohm Microcell HD, an additional Arbin 128 channel battery test system, and a new Branson ultrasonic welder.